Technology | PET Imaging | December 05, 2018

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET

Artificial intelligence-based technology allows faster PET scans while enhancing image quality

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET

December 5, 2018 — Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle Medical also recently secured approval to affix the CE Mark on SubtlePET to begin marketing in the European Economic Area without restrictions.

SubtlePET’s artificial intelligence (AI)-powered technology allows hospitals and imaging centers to enhance images from faster positron emission tomography (PET) scans, leading to an improved patient experience during nuclear imaging procedures, while boosting exam throughput and provider profitability. SubtlePET is currently in pilot clinical use in multiple university hospitals and imaging centers in the U.S. and abroad.

“Focusing Subtle Medical's SubtlePET AI platform on faster image acquisition, we have been able to dramatically increase PET scan efficiency and provide a superior patient experience. SubtlePET  technology allows us to scan a patient four times faster than normal, yet maintain equal image quality, not otherwise impacting work flow,” said Michael Brant-Zawadzki, M.D., FACR, Hoag Hospital, Newport Beach, Calif. “This creates immediate ROI [return on investment] benefit for our hospital and a compelling value proposition. I’m looking forward to seeing more groundbreaking technology from the Subtle team.”

Subtle Medical’s AI solution:

  • Enables completion of more exams in a day compared to conventional PET imaging without the need for capital expenditures;

  • Reduces patient time in the scanner; and

  • Helps hospitals and imaging centers enhance their bottom line in today’s competitive healthcare environment.  

The company’s technology utilizes deep learning algorithms that integrate seamlessly with any OEM scanner and picture archiving and communication system (PACS) to enhance images during acquisition, without any interruption or alteration in the imaging specialists’ workflow.  SubtlePET delivers a significant improvement in the image quality of noisy images resulting from shorter scans, which is particularly beneficial for children and those undergoing repeat PET exams.

SubtlePET is the first product in Subtle Medical’s growing portfolio of new AI technologies to receive FDA clearance. The company is developing additional products to be submitted for FDA clearance.  A second product currently undergoing clinical evaluation is SubtleMR, which allows imaging centers to significantly accelerate magnetic resonance imaging (MRI) scans using the company’s AI solutions. SubtleGAD is also being developed to reduce gadolinium dosage during imaging procedures.

For more information: www.subtlemedical.com


Related Content

News | Artificial Intelligence

November 23, 2022 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today ...

Home November 23, 2022
Home
News | Artificial Intelligence

November 21, 2022 — Artificial intelligence can improve diagnosis and treatment for patients, but first the AI-enabled ...

Home November 21, 2022
Home
News | Artificial Intelligence

November 16, 2022 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today ...

Home November 16, 2022
Home
News | Artificial Intelligence

November 16, 2022 — A study published in Nature Medicine reports the ability of a smartwatch ECG to accurately detect ...

Home November 16, 2022
Home
News | Artificial Intelligence

September 29, 2022 — Researchers at Mayo Clinic used artificial intelligence (AI) to evaluate patients’ ...

Home September 29, 2022
Home
News | Artificial Intelligence

September 22, 2022 — Medical imaging specialist Avicenna.AI announced a groundbreaking partnership with the MedTech ...

Home September 22, 2022
Home
News | Artificial Intelligence

September 2, 2022 — In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by ...

Home September 02, 2022
Home
News | Artificial Intelligence

August 29, 2022 — In a first-of-its-kind randomized clinical trial led by researchers at the Smidt Heart Institute and ...

Home August 29, 2022
Home
News | Artificial Intelligence

August 18, 2022 — Six digital healthcare start-ups from five countries have officially become the first cohort of the ...

Home August 18, 2022
Home
News | Artificial Intelligence

August 16, 2022 — Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis ...

Home August 16, 2022
Home
Subscribe Now